Intercepting Cancer Earlier: Why Pharma Must Lead the Early Detection Agenda
- Reframing early detection as a strategic extension of drug development, not a departure from it
- Using ctDNA and emerging assays to guide earlier intervention, adjuvant decisions, and monitoring
- Aligning innovation with the ambition to eliminate cancer as a cause of death